Genitourinary Cancers

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Joseph Jacob, MD, MCR, discusses the potential role of an intravesical gemcitabine delivery system for BCG-unresponsive non–muscle-invasive bladder cancer.

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Hans Hammers, MD, PhD, discusses the efficacy, safety, and clinical utilization of IO/IO and IO/TKI combinations in advanced clear-cell RCC.

Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.